Immunity drives TET1 regulation in cancer through NF-kappaB.

[en] Ten-eleven translocation enzymes (TET1, TET2, and TET3), which induce DNA demethylation and gene regulation by converting 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC), are often down-regulated in cancer. We uncover, in basal-like breast cancer (BLBC), genome-wide 5hmC changes related to TET1 regulation. We further demonstrate that TET1 repression is associated with high expression of immune markers and high infiltration by immune cells. We identify in BLBC tissues an anticorrelation between TET1 expression and the major immunoregulator family nuclear factor kappaB (NF-kappaB). In vitro and in mice, TET1 is down-regulated in breast cancer cells upon NF-kappaB activation through binding of p65 to its consensus sequence in the TET1 promoter. We lastly show that these findings extend to other cancer types, including melanoma, lung, and thyroid cancers. Together, our data suggest a novel mode of regulation for TET1 in cancer and highlight a new paradigm in which the immune system can influence cancer cell epigenetics.

Disciplines :

Biochemistry, biophysics & molecular biology

Author, co-author :

Collignon, Evelyne ^✱

Canale, Annalisa ^✱; Université de Liège - ULiège > Département des sciences cliniques > Labo de biologie des tumeurs et du développement

Al Wardi, Clemence

Bizet, Martin

Calonne, Emilie

Dedeurwaerder, Sarah

Garaud, Soizic

Naveaux, Celine

Barham, Whitney

Wilson, Andrew

More authors (8 more)

^✱ These authors have contributed equally to this work.

Language :

English

Title :

Immunity drives TET1 regulation in cancer through NF-kappaB.

Publication date :

2018

Journal title :

Science Advances

eISSN :

2375-2548

Publisher :

American Association for the Advancement of Science (AAAS), United States

Volume :

Issue :

Pages :

eaap7309

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 19 September 2018

Statistics

Number of views

87 (7 by ULiège)

Number of downloads

43 (4 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

A. G. Rivenbark, S. M. O’Connor, W. B. Coleman, Molecular and cellular heterogeneity in breast cancer: Challenges for personalized medicine. Am. J. Pathol. 183, 1113–1124 (2013).
C. M. Perou, T. Sørlie, M. B. Eisen, M. van de Rijn, S. S. Jeffrey, C. A. Rees, J. R. Pollack, D. T. Ross, H. Johnsen, L. A. Akslen, Ø. Fluge, A. Pergamenschikov, C. Williams, S. X. Zhu, P. E. Lønning, A.-L. Børresen-Dale, P. O. Brown, D. Botstein, Molecular portraits of human breast tumours. Nature 406, 747–752 (2000).
T. Sørlie, C. M. Perou, R. Tibshirani, T. Aas, S. Geisler, H. Johnsen, T. Hastie, M. B. Eisen, M. van de Rijn, S. S. Jeffrey, T. Thorsen, H. Quist, J. C. Matese, P. O. Brown, D. Botstein, P. E. Lønning, A.-L. Børresen-Dale, Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. U.S.A. 98, 10869–10874 (2001).
C. Sotiriou, S.-Y. Neo, L. M. McShane, E. L. Korn, P. M. Long, A. Jazaeri, P. Martiat, S. B. Fox, A. L. Harris, E. T. Liu, Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc. Natl. Acad. Sci. U.S.A. 100, 10393–10398 (2003).
T. Sørlie, R. Tibshirani, J. Parker, T. Hastie, J. S. Marron, A. Nobel, S. Deng, H. Johnsen, R. Pesich, S. Geisler, J. Demeter, C. M. Perou, P. E. Lønning, P. O. Brown, A.-L. Børresen-Dale, D. Botstein, Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. U.S.A. 100, 8418–8423 (2003).
N. P. Tobin, J. C. Harrell, J. Lövrot, S. Egyhazi Brage, M. Frostvik Stolt, L. Carlsson, Z. Einbeigi, B. Linderholm, N. Loman, M. Malmberg, T. Walz, M. Fernö, C. M. Perou, J. Bergh, T. Hatschek, L. S. Lindström; TEX Trialists Group, Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival. Ann. Oncol. 26, 81–88 (2015).
M. Berdasco, M. Esteller, Aberrant epigenetic landscape in cancer: How cellular identity goes awry. Dev. Cell 19, 698–711 (2010).
R. B. Lorsbach, J. Moore, S. Mathew, S. C. Raimondi, S. T. Mukatira, J. R. Downing, TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23). Leukemia 17, 637–641 (2003).
M. Münzel, D. Globisch, T. Carell, 5-Hydroxymethylcytosine, the sixth base of the genome. Angew. Chem. Int. Ed. Engl. 50, 6460–6468 (2011).
M. Tahiliani, K. P. Koh, Y. Shen, W. A. Pastor, H. Bandukwala, Y. Brudno, S. Agarwal, L. M. Iyer, D. R. Liu, L. Aravind, A. Rao, Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324, 930–935 (2009).
S. Ito, A. C. D’Alessio, O. V. Taranova, K. Hong, L. C. Sowers, Y. Zhang, Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature 466, 1129–1133 (2010).
L. Li, C. Li, H. Mao, Z. Du, W. Y. Chan, P. Murray, B. Luo, A. T. Chan, T. S. Mok, F. K. Chan, R. F. Ambinder, Q. Tao, Epigenetic inactivation of the CpG demethylase TET1 as a DNA methylation feedback loop in human cancers. Sci. Rep. 6, 26591 (2016).
Y. Xu, F. Wu, L. Tan, L. Kong, L. Xiong, J. Deng, A. Barbera, L. Zheng, H. Zhang, S. Huang, J. Min, T. Nicholson, T. Chen, G. Xu, Y. Shi, K. Zhang, Y. G. Shi, Genome-wide regulation of 5hmC, 5mC, and gene expression by Tet1 hydroxylase in mouse embryonic stem cells. Mol. Cell 42, 451–464 (2011).
J. U. Guo, Y. Su, C. Zhong, G.-L. Ming, H. Song, Hydroxylation of 5-methylcytosine by TET1 promotes active DNA demethylation in the adult brain. Cell 145, 423–434 (2011).
W. A. Pastor, L. Aravind, A. Rao, TETonic shift: Biological roles of TET proteins in DNA demethylation and transcription. Nat. Rev. Mol. Cell Biol. 14, 341–356 (2013).
M. C. Haffner, A. Chaux, A. K. Meeker, D. M. Esopi, J. Gerber, L. G. Pellakuru, A. Toubaji, P. Argani, C. Iacobuzio-Donahue, W. G. Nelson, G. J. Netto, A. M. De Marzo, S. Yegnasubramanian, Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers. Oncotarget 2, 627–637 (2011).
C. G. Lian, Y. Xu, C. Ceol, F. Wu, A. Larson, K. Dresser, W. Xu, L. Tan, Y. Hu, Q. Zhan, C.-W. Lee, D. Hu, B. Q. Lian, S. Kleffel, Y. Yang, J. Neiswender, A. J. Khorasani, R. Fang, C. Lezcano, L. M. Duncan, R. A. Scolyer, J. F. Thompson, H. Kakavand, Y. Houvras, L. Zon, M. C. Mihm Jr., U. B. Kaiser, T. Schatton, B. A. Woda, G. F. Murphy, Y. G. Shi, Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell 150, 1135–1146 (2012).
C. H. Hsu, K. L. Peng, M. L. Kang, Y. R. Chen, Y. C. Yang, C. H. Tsai, C. S. Chu, Y. M. Jeng, Y. T. Chen, F. M. Lin, H. D. Huang, Y. Y. Lu, Y. C. Teng, S. T. Lin, R. K. Lin, F. M. Tang, S. B. Lee, H. M. Hsu, J. C. Yu, P. W. Hsiao, L. J. Juan, TET1 suppresses cancer invasion by activating the tissue inhibitors of metalloproteinases. Cell Rep. 2, 568–579 (2012).
F. Neri, D. Dettori, D. Incarnato, A. Krepelova, S. Rapelli, M. Maldotti, C. Parlato, P. Paliogiannis, S. Oliviero, TET1 is a tumour suppressor that inhibits colon cancer growth by derepressing inhibitors of the WNT pathway. Oncogene 34, 4168–4176 (2015).
L. Yang, S.-J. Yu, Q. Hong, Y. Yang, Z.-M. Shao, Reduced expression of TET1, TET2, TET3 and TDG mRNAs are associated with poor prognosis of patients with early breast cancer. PLOS ONE 10, e0133896 (2015).
H.-G. Lu, W. Zhan, L. Yan, R.-Y. Qin, Y.-P. Yan, Z.-J. Yang, G.-C. Liu, G.-Q. Li, H.-F. Wang, X.-L. Li, Z. Li, L. Gao, G.-Q. Chen, TET1 partially mediates HDAC inhibitor-induced suppression of breast cancer invasion. Mol. Med. Rep. 10, 2595–2600 (2014).
Y. Sang, C. Cheng, X.-F. Tang, M.-F. Zhang, X.-B. Lv, Hypermethylation of TET1 promoter is a new diagnosic marker for breast cancer metastasis. Asian Pac. J. Cancer Prev. 16, 1197–1200 (2015).
Y.-F. Pei, Y. Lei, X.-Q. Liu, MiR-29a promotes cell proliferation and EMT in breast cancer by targeting ten eleven translocation 1. Biochim. Biophys. Acta 1862, 2177–2185 (2016).
M. Sun, C.-X. Song, H. Huang, C. A. Frankenberger, D. Sankarasharma, S. Gomes, P. Chen, J. Chen, K. K. Chada, C. He, M. R. Rosner, HMGA2/TET1/HOXA9 signaling pathway regulates breast cancer growth and metastasis. Proc. Natl. Acad. Sci. U.S.A. 110, 9920–9925 (2013).
B. Lakshmi Narendra, K. Eshvendar Reddy, S. Shantikumar, S. Ramakrishna, Immune system: A double-edged sword in cancer. Inflamm. Res. 62, 823–834 (2013).
B. Melichar, H. Študentová, H. Kalábová, D. Vitásková, P. Čermáková, H. Hornychová, A. Ryška, Predictive and prognostic significance of tumor-infiltrating lymphocytes in patients with breast cancer treated with neoadjuvant systemic therapy. Anticancer Res. 34, 1115–1125 (2014).
D. A. Oble, R. Loewe, P. Yu, M. C. Mihm Jr., Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human melanoma. Cancer Immunol. Res. 9, 3 (2009).
J. Galon, A. Costes, F. Sanchez-Cabo, A. Kirilovsky, B. Mlecnik, C. Lagorce-Pagès, M. Tosolini, M. Camus, A. Berger, P. Wind, F. Zinzindohoué, P. Bruneval, P.-H. Cugnenc, Z. Trajanoski, W.-H. Fridman, F. Pagès, Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960–1964 (2006).
M. Dany, R. Nganga, A. Chidiac, E. Hanna, S. Matar, D. Elston, Advances in immunotherapy for melanoma management. Hum. Vaccines Immunother. 12, 2501–2511 (2016).
S. Gerondakis, U. Siebenlist, Roles of the NF-kB pathway in lymphocyte development and function. Cold Spring Harb. Perspect. Biol. 2, a000182 (2010).
A. Hoffmann, D. Baltimore, Circuitry of nuclear factor kB signaling. Immunol. Rev. 210, 171–186 (2006).
A. Oeckinghaus, S. Ghosh, The NF-kB family of transcription factors and its regulation. Cold Spring Harb. Perspect. Biol. 1, a000034 (2009).
B. P. Ashburner, S. D. Westerheide, A. S. Baldwin Jr., The p65 (RelA) subunit of NF-kB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression. Mol. Cell. Biol. 21, 7065–7077 (2001).
S. I. Grivennikov, F. R. Greten, M. Karin, Immunity, inflammation, and cancer. Cell 140, 883–899 (2010).
B. Hoesel, J. A. Schmid, The complexity of NF-kB signaling in inflammation and cancer. Mol. Cancer 12, 86 (2013).
A. Mantovani, Molecular pathways linking inflammation and cancer. Curr. Mol. Med. 10, 369–373 (2010).
D. M. Brantley, C.-L. Chen, R. S. Muraoka, P. B. Bushdid, J. L. Bradberry, F. Kittrell, D. Medina, L. M. Matrisian, L. D. Kerr, F. E. Yull, Nuclear factor-kB (NF-kB) regulates proliferation and branching in mouse mammary epithelium. Mol. Biol. Cell 12, 1445–1455 (2001).
N. Yamaguchi, T. Ito, S. Azuma, E. Ito, R. Honma, Y. Yanagisawa, A. Nishikawa, M. Kawamura, J.-I. Imai, S. Watanabe, K. Semba, J.-I. Inoue, Constitutive activation of nuclear factor-kB is preferentially involved in the proliferation of basal-like subtype breast cancer cell lines. Cancer Sci. 100, 1668–1674 (2009).
M. Liu, T. Sakamaki, M. C. Casimiro, N. E. Willmarth, A. A. Quong, X. Ju, J. Ojeifo, X. Jiao, W.-S. Yeow, S. Katiyar, L. A. Shirley, D. Joyce, M. P. Lisanti, C. Albanese, R. G. Pestell, The canonical NF-kB pathway governs mammary tumorigenesis in transgenic mice and tumor stem cell expansion. Cancer Res. 70, 10464–10473 (2010).
L. Connelly, W. Barham, H. M. Onishko, T. Sherrill, L. A. Chodosh, T. S. Blackwell, F. E. Yull, Inhibition of NF-kappa B activity in mammary epithelium increases tumor latency and decreases tumor burden. Oncogene 30, 1402–1412 (2011).
M. Karin, Nuclear factor-kB in cancer development and progression. Nature 441, 431–436 (2006).
H. L. Chua, P. Bhat-Nakshatri, S. E. Clare, A. Morimiya, S. Badve, H. Nakshatri, NF-kB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: Potential involvement of ZEB-1 and ZEB-2. Oncogene 26, 711–724 (2007).
W. E. Naugler, M. Karin, NF-kB and cancer—Identifying targets and mechanisms. Curr. Opin. Genet. Dev. 18, 19–26 (2008).
D. Joyce, C. Albanese, J. Steer, M. Fu, B. Bouzahzah, R. G. Pestell, NF-kB and cell-cycle regulation: The cyclin connection. Cytokine Growth Factor Rev. 12, 73–90 (2001).
S. A. Vlahopoulos, O. Cen, N. Hengen, J. Agan, M. Moschovi, E. Critselis, M. Adamaki, F. Bacopoulou, J. A. Copland, I. Boldogh, M. Karin, G. P. Chrousos, Dynamic aberrant NF-kB spurs tumorigenesis: A new model encompassing the microenvironment. Cytokine Growth Factor Rev. 26, 389–403 (2015).
J. Y. Zhang, S. Tao, R. Kimmel, P. A. Khavari, CDK4 regulation by TNFR1 and JNK is required for NF-kB–mediated epidermal growth control. J. Cell Biol. 168, 561–566 (2005).
S. Maeda, H. Kamata, J.-L. Luo, H. Leffert, M. Karin, IKKb couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 121, 977–990 (2005).
W. Shibata, S. Takaishi, S. Muthupalani, D. M. Pritchard, M. T. Whary, A. B. Rogers, J. G. Fox, K. S. Betz, K. H. Kaestner, M. Karin, T. C. Wang, Conditional deletion of IkB-kinase-b accelerates Helicobacter-dependent gastric apoptosis, proliferation, and preneoplasia. Gastroenterology 138, 1022–1034.e10 (2010).
D. Capece, D. Verzella, A. Tessitore, E. Alesse, C. Capalbo, F. Zazzeroni, Cancer secretome and inflammation: The bright and the dark sides of NF-kB. Semin. Cell Dev. Biol. 78, 51–61 (2018).
S. Dedeurwaerder, C. Desmedt, E. Calonne, S. K. Singhal, B. Haibe-Kains, M. Defrance, S. Michiels, M. Volkmar, R. Deplus, J. Luciani, F. Lallemand, D. Larsimont, J. Toussaint, S. Haussy, F. Rothé, G. Rouas, O. Metzger, S. Majjaj, K. Saini, P. Putmans, G. Hames, N. van Baren, P. G. Coulie, M. Piccart, C. Sotiriou, F. Fuks, DNA methylation profiling reveals a predominant immune component in breast cancers. EMBO Mol. Med. 3, 726–741 (2011).
K. B. Chiappinelli, P. L. Strissel, A. Desrichard, H. Li, C. Henke, B. Akman, A. Hein, N. S. Rote, L. M. Cope, A. Snyder, V. Makarov, S. Buhu, D. J. Slamon, J. D. Wolchok, D. M. Pardoll, M. W. Beckmann, C. A. Zahnow, T. Merghoub, T. A. Chan, S. B. Baylin, R. Strick, Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Cell 162, 974–986 (2015).
D. Roulois, H. L. Yau, R. Singhania, Y. Wang, A. Danesh, S. Y. Shen, H. Han, G. Liang, P. A. Jones, T. J. Pugh, C. O’Brien, D. D. De Carvalho, DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts. Cell 162, 961–973 (2015).
K. B. Chiappinelli, C. A. Zahnow, N. Ahuja, S. B. Baylin, Combining epigenetic and immunotherapy to combat cancer. Cancer Res. 76, 1683–1689 (2016).
Q. Zhang, K. Zhao, Q. Shen, Y. Han, Y. Gu, X. Li, D. Zhao, Y. Liu, C. Wang, X. Zhang, X. Su, J. Liu, W. Ge, R. L. Levine, N. Li, X. Cao, Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6. Nature 525, 389–393 (2015).
K. Ichiyama, T. Chen, X. Wang, X. Yan, B.-S. Kim, S. Tanaka, D. Ndiaye-Lobry, Y. Deng, Y. Zou, P. Zheng, Q. Tian, I. Aifantis, L. Wei, C. Dong, The methylcytosine dioxygenase Tet2 promotes DNA demethylation and activation of cytokine gene expression in T cells. Immunity 42, 613–626 (2015).
S. A. Carty, M. Gohil, L. B. Banks, R. M. Cotton, M. E. Johnson, E. Stelekati, A. D. Wells, E. J. Wherry, G. A. Koretzky, M. S. Jordan, The loss of TET2 promotes CD8+ T cell memory differentiation. J. Immunol. 200, 82–91 (2018).
C. Yang, Z. Li, W. Kang, Y. Tian, Y. Yan, W. Chen, TET1 and TET3 are essential in induction of Th2-type immunity partly through regulation of IL-4/13A expression in zebrafish model. Gene 591, 201–208 (2016).
B. Delatte, J. Jeschke, M. Defrance, M. Bachman, C. Creppe, E. Calonne, M. Bizet, R. Deplus, L. Marroquí, M. Libin, M. Ravichandran, F. Mascart, D. L. Eizirik, A. Murrell, T. P. Jurkowski, F. Fuks, Genome-wide hydroxymethylcytosine pattern changes in response to oxidative stress. Sci. Rep. 5, 12714 (2015).
J. Jeschke, M. Bizet, C. Desmedt, E. Calonne, S. Dedeurwaerder, S. Garaud, A. Koch, D. Larsimont, R. Salgado, G. Van den Eynden, K. W. Gallo, G. Bontempi, M. Defrance, C. Sotiriou, F. Fuks, DNA methylation–based immune response signature improves patient diagnosis in multiple cancers. J. Clin. Invest. 127, 3090–3102 (2017).
C. E. Hellweg, A. Arenz, S. Bogner, C. Schmitz, C. Baumstark-Khan, Activation of nuclear factor kB by different agents: Influence of culture conditions in a cell-based assay. Ann. N. Y. Acad. Sci. 1091, 191–204 (2006).
D. H. Lee, A. L. Goldberg, Proteasome inhibitors: Valuable new tools for cell biologists. Trends Cell Biol. 8, 397–403 (1998).
W. Barham, L. Chen, O. Tikhomirov, H. Onishko, L. Gleaves, T. P. Stricker, T. S. Blackwell, F. E. Yull, Aberrant activation of NF-kB signaling in mammary epithelium leads to abnormal growth and ductal carcinoma in situ. BMC Cancer 15, 647 (2015).
H. Jókai, M. Marschalkó, J. Csomor, J. Szakonyi, O. Kontár, G. Barna, S. Kárpáti, P. Holló, Tissue-specific homing of immune cells in malignant skin tumors. Pathol. Oncol. Res. 18, 749–759 (2012).
S. Imam, R. Paparodis, D. Sharma, J. C. Jaume, Lymphocytic profiling in thyroid cancer provides clues for failure of tumor immunity. Endocr. Relat. Cancer 21, 505–516 (2014).
J. Kargl, S. E. Busch, G. H. Y. Yang, K.-H. Kim, M. L. Hanke, H. E. Metz, J. J. Hubbard, S. M. Lee, D. K. Madtes, M. W. McIntosh, A. M. Houghton, Neutrophils dominate the immune cell composition in non-small cell lung cancer. Nat. Commun. 8, 14381 (2017).
Y. Kudo, K. Tateishi, K. Yamamoto, S. Yamamoto, Y. Asaoka, H. Ijichi, G. Nagae, H. Yoshida, H. Aburatani, K. Koike, Loss of 5-hydroxymethylcytosine is accompanied with malignant cellular transformation. Cancer Sci. 103, 670–676 (2012).
B. Thienpont, J. Steinbacher, H. Zhao, F. D’Anna, A. Kuchnio, A. Ploumakis, B. Ghesquière, L. Van Dyck, B. Boeckx, L. Schoonjans, E. Hermans, F. Amant, V. N. Kristensen, K. P. Koh, M. Mazzone, M. L. Coleman, T. Carell, P. Carmeliet, D. Lambrechts, Tumour hypoxia causes DNA hypermethylation by reducing TET activity. Nature 537, 63–68 (2016).
A. Sica, A. Mantovani, Macrophage plasticity and polarization: In vivo veritas. J. Clin. Invest. 122, 787–795 (2012).
A. Mantovani, A. Sica, S. Sozzani, P. Allavena, A. Vecchi, M. Locati, The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 25, 677–686 (2004).
F. Chen, K. Beezhold, V. Castranova, Tumor promoting or tumor suppressing of NF-k B, a matter of cell context dependency. Int. Rev. Immunol. 27, 183–204 (2008).
Y. Liu, M. W. Mayo, A. S. Nagji, P. W. Smith, C. S. Ramsey, D. Li, D. R. Jones, Phosphorylation of RelA/p65 promotes DNMT-1 recruitment to chromatin and represses transcription of the tumor metastasis suppressor gene BRMS1. Oncogene 31, 1143–1154 (2012).
R. Yang, C. Qu, Y. Zhou, J. E. Konkel, S. Shi, Y. Liu, C. Chen, S. Liu, D. Liu, Y. Chen, E. Zandi, W. Chen, Y. Zhou, S. Shi, Hydrogen sulfide promotes Tet1- and Tet2-mediated Foxp3 demethylation to drive regulatory T cell differentiation and maintain immune homeostasis. Immunity 43, 251–263 (2015).
D. W. Huang, B. T. Sherman, R. A. Lempicki, Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44–57 (2009).
A. M. Newman, C. L. Liu, M. R. Green, A. J. Gentles, W. Feng, Y. Xu, C. D. Hoang, M. Diehn, A. A. Alizadeh, Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods 12, 453–457 (2015).
S. J. Van Laere, I. Van der Auwera, G. G. Van den Eynden, H. J. Elst, J. Weyler, A. L. Harris, P. van Dam, E. A. Van Marck, P. B. Vermeulen, L. Y. Dirix, Nuclear factor-kB signature of inflammatory breast cancer by cDNA microarray validated by quantitative real-time reverse transcription-PCR, immunohistochemistry, and nuclear factor-kB DNA-binding. Clin. Cancer Res. 12, 3249–3256 (2006).
M. M. Mohamed, Monocytes conditioned media stimulate fibronectin expression and spreading of inflammatory breast cancer cells in three-dimensional culture: A mechanism mediated by IL-8 signaling pathway. Cell Commun. Signal 10, 3 (2012).
H. B. Sadowski, M. Z. Gilman, Cell-free activation of a DNA-binding protein by epidermal growth factor. Nature 362, 79–83 (1993).
W.-G. Deng, Y. Zhu, A. Montero, K. K. Wu, Quantitative analysis of binding of transcription factor complex to biotinylated DNA probe by a streptavidin–agarose pulldown assay. Anal. Biochem. 323, 12–18 (2003).
L. Buisseret, C. Desmedt, S. Garaud, M. Fornili, X. Wang, G. Vanden Eyden, A. de Wind, S. Duquenne, A. Boisson, C. Naveaux, F. Rothé, S. Rorive, C. Decaestecker, D. Larsimont, M. Piccart-Gebhart, E. Biganzoli, C. Sotiriou, K. Willard-Gallo, Reliability of tumor-infiltrating lymphocyte and tertiary lymphoid structure assessment in human breast cancer. Mod. Pathol. 30, 1204–1212 (2017).
O. Van Grembergen, M. Bizet, E. J. de Bony, E. Calonne, P. Putmans, S. Brohée, C. Olsen, M. Guo, G. Bontempi, C. Sotiriou, M. Defrance, F. Fuks, Portraying breast cancers with long noncoding RNAs. Sci. Adv. 2, e1600220 (2016).
E. M. Price, A. M. Cotton, L. L. Lam, P. Farré, E. Emberly, C. J. Brown, W. P. Robinson, M. S. Kobor, Additional annotation enhances potential for biologically-relevant analysis of the Illumina Infinium HumanMethylation450 BeadChip array. Epigenetics Chromatin 6, 4 (2013).